Endocrinology Advisor1d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
Renal & Urology News14d
Real-World Effectiveness of GLP-1 RA vs DPP4i in Moderate to Severe CKD Explored
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
Monthly Prescribing Reference27d
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
The active GLP-1 RA prescription group had a significantly lower risk for 30-day readmission and 180-day postoperative wound dehiscence and postoperative hematoma after matching. HealthDay News ...
Yahoo Finance10d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...
Monthly Prescribing Reference10d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...
Hosted on MSN28d
Perioperative GLP-1 RA Use Reduces Risk for Complications in Patients With Diabetes
an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted readmission, wound dehiscence, and hematoma, according to a ...